The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Anti–high mobility group box‐1 antibody therapy for traumatic brain injury
Abstract
Objective: High mobility group box‐1 (HMGB1) plays an important role in triggering inflammatory responses in many types of diseases. In this study, we examined the involvement of HMGB1 in traumatic brain injury (TBI) and evaluated the ability of intravenously administered neutralizing anti‐HMGB1 monoclonal antibody (mAb) to attenuate brain injury. Methods: Traumatic brain injury was induced in rats or mice by fluid percussion. Anti‐HMGB1 mAb or control mAb was administered intravenously after TBI. Results: Anti‐HMGB1 mAb remarkably inhibited fluid percussion‐induced brain edema in rats, as detected by T2‐weighted magnetic resonance imaging; this was associated with inhibition of HMGB1 translocation, protection of blood–brain barrier (BBB) integrity, suppression of inflammatory molecule expression, and improvement of motor function. In contrast, intravenous injection of recombinant HMGB1 dose‐dependently produced the opposite effects. Experiments using receptor for advanced glycation end product (RAGE)−/−, toll‐like receptor‐4 (TLR4)−/−, and TLR2−/− mice suggested the involvement of RAGE as the predominant receptor for HMGB1. Interpretation: Anti‐HMGB1 mAb may provide a novel and effective therapy for TBI by protecting against BBB disruption and reducing the inflammatory responses induced by HMGB1. ANN NEUROL 2012;72:373–384
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25752 · Cited by 1,151
Self-citationYang, Y., Estrada, E. Y., Thompson, J. F., Liu, W., & Rosenberg, G. A. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600375 · Cited by 1,060
Clinical trials in head injury
Narayan, R. K., Michel, M. E., Ansell, B., Baethmann, A., Biegon, A., Bracken, M. B., Bullock, M. R., Choi, S. C., Clifton, G. L., Contant, C. F., et al. (2002) · Journal of Neurotrauma · doi:10.1089/089771502753754037 · Cited by 913
Blood–brain barrier breakdown as a therapeutic target in traumatic brain injury
Shlosberg, D., Benifla, M., Kaufer, D., & Friedman, A. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.74 · Cited by 897
HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2
Yu, M., Wang, H., Ding, A., Golenbock, D. T., Latz, E., Czura, C. J., Fenton, M. J., Tracey, K. J., & Yang, H. (2006) · Shock · doi:10.1097/01.shk.0000225404.51320.82 · Cited by 832
Metalloproteinases: Mediators of Pathology and Regeneration in the CNS
Yong, V. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1807 · Cited by 582
Head injury and the risk of AD in the MIRAGE study
Guo, Z., Cupples, L. A., Kurz, A., Auerbach, S. H., Volicer, L., Chui, H., Green, R. C., Sadovnick, A. D., Duara, R., DeCarli, C., et al. (2000) · Neurology · doi:10.1212/wnl.54.6.1316 · Cited by 506
Depression and cognitive complaints following mild traumatic brain injury
Silver, J. M., McAllister, T. W., & Arciniegas, D. B. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08111676 · Cited by 315 · cited 1×
“In addition, patients with TBI often experience post-traumatic epilepsy(36) and impairment in cognitive function.(37) Moreover, TBI has been considered a risk factor for Alzheimer disease.”
Background
Cited by
Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift
Jassam, Y. N., Izzy, S., Whalen, M., McGavern, D. B., & El Khoury, J. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.010 · Cited by 799
A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics
Mutua, V., & Gershwin, L. J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08804-7 · Cited by 639
Targeting Inflammation Driven by HMGB1
Yang, H., Wang, H., & Andersson, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00484 · Cited by 636
Innate immune responses to trauma
Huber-Lang, M., Lambris, J. D., & Ward, P. A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0064-8 · Cited by 599
Pathophysiology and treatment of cerebral edema in traumatic brain injury
Jha, R. M., Kochanek, P. M., & Simard, J. M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.08.004 · Cited by 481
Metadata
- Authors
- Okuma, Y., Liu, K., Wake, H., Zhang, J., Maruo, T., Date, I., Yoshino, T., Ohtsuka, A., Otani, N., Tomura, S., Shima, K., Yamamoto, Y., Yamamoto, H., Takahashi, H. K., Mori, S., & Nishibori, M.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-08-22
- Volume
- 72
- Issue
- 3
- Pages
- 373-384
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2012763966
- Cited by
- 236
- References
- 10
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti–high mobility group box‐1 antibody therapy for traumatic brain injury. https://app.cochat.ai/papers/10.1002/ana.23602
- The paper
- Okuma, Y., Liu, K., Wake, H., Zhang, J., Maruo, T., Date, I., Yoshino, T., Ohtsuka, A., Otani, N., Tomura, S., Shima, K., Yamamoto, Y., Yamamoto, H., Takahashi, H. K., Mori, S., & Nishibori, M. (2012). Anti–high mobility group box‐1 antibody therapy for traumatic brain injury. Annals of Neurology. https://doi.org/10.1002/ana.23602
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.